Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2009-08-13
2011-11-15
Chandra, Gyan (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013500, C530S350000
Reexamination Certificate
active
08058229
ABSTRACT:
In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
REFERENCES:
patent: 4973577 (1990-11-01), Vale, Jr. et al.
patent: 5118667 (1992-06-01), Adams et al.
patent: 5658876 (1997-08-01), Crowley et al.
patent: 5824637 (1998-10-01), Crowley et al.
patent: 5847078 (1998-12-01), Eto et al.
patent: 5885794 (1999-03-01), Mathews et al.
patent: 6093547 (2000-07-01), Jin et al.
patent: 6132988 (2000-10-01), Sugino et al.
patent: 6162896 (2000-12-01), Mathews et al.
patent: 6451334 (2002-09-01), Perrine
patent: 6599876 (2003-07-01), Kojima
patent: 6605699 (2003-08-01), Ni et al.
patent: 6656475 (2003-12-01), Lee et al.
patent: 6692925 (2004-02-01), Miyazono et al.
patent: 6696260 (2004-02-01), Lee et al.
patent: 6835544 (2004-12-01), Mathews et al.
patent: 6891082 (2005-05-01), Lee et al.
patent: 7192717 (2007-03-01), Hill et al.
patent: 7202210 (2007-04-01), Wolfman et al.
patent: 7261893 (2007-08-01), Veldman et al.
patent: 7320789 (2008-01-01), Aghajanian et al.
patent: 7560441 (2009-07-01), Wolfman et al.
patent: 7612041 (2009-11-01), Knopf et al.
patent: 2003/0083251 (2003-05-01), Westenfelder
patent: 2003/0144203 (2003-07-01), Bowen
patent: 2004/0197828 (2004-10-01), Gaddy
patent: 2004/0209805 (2004-10-01), Phillips et al.
patent: 2004/0223966 (2004-11-01), Wolfman et al.
patent: 2005/0257278 (2005-11-01), Lee et al.
patent: 2006/0210657 (2006-09-01), Chou
patent: 2007/0048830 (2007-03-01), Gilbert et al.
patent: 2007/0149455 (2007-06-01), Wolfman et al.
patent: 2007/0172956 (2007-07-01), Magari et al.
patent: 2007/0184052 (2007-08-01), Lin et al.
patent: 2007/0249022 (2007-10-01), Knopf et al.
patent: 2007/0275895 (2007-11-01), Duan et al.
patent: 2007/0292885 (2007-12-01), Bejanin et al.
patent: 2008/0021104 (2008-01-01), Tarallo
patent: 2008/0075692 (2008-03-01), Perrine
patent: 2008/0089897 (2008-04-01), Wolfman
patent: 2008/0139590 (2008-06-01), Qian et al.
patent: 2009/0005308 (2009-01-01), Knopf et al.
patent: 2009/0017019 (2009-01-01), Shields et al.
patent: 2009/0047281 (2009-02-01), Sherman
patent: 2009/0074768 (2009-03-01), Knopf et al.
patent: 2009/0087433 (2009-04-01), Wolfman et al.
patent: 2009/0098113 (2009-04-01), Knopf et al.
patent: 2009/0099086 (2009-04-01), Knopf et al.
patent: 2009/0118188 (2009-05-01), Knopf et al.
patent: 2009/0142333 (2009-06-01), Knopf et al.
patent: 2009/0148436 (2009-06-01), LaVallie et al.
patent: 2009/0163417 (2009-06-01), Sherman
patent: WO-92/20793 (1992-11-01), None
patent: WO-9510611 (1995-04-01), None
patent: WO-95/29685 (1995-11-01), None
patent: WO-99/06559 (1999-02-01), None
patent: WO-02/10214 (2002-02-01), None
patent: WO-02/43759 (2002-06-01), None
patent: WO-02/085306 (2002-10-01), None
patent: WO-03/006057 (2003-01-01), None
patent: WO-03/053219 (2003-07-01), None
patent: WO-03/072808 (2003-09-01), None
patent: WO-2004/039948 (2004-05-01), None
patent: WO-2004/108157 (2004-12-01), None
patent: WO-2005/009460 (2005-02-01), None
patent: WO-2005/028517 (2005-03-01), None
patent: WO-2005/094871 (2005-10-01), None
patent: WO-2005/097825 (2005-10-01), None
patent: WO-2006002387 (2006-01-01), None
patent: WO-2006/020844 (2006-02-01), None
patent: WO-2006/039400 (2006-04-01), None
patent: WO-2006/083183 (2006-08-01), None
patent: WO-2006/088972 (2006-08-01), None
patent: WO-2007/053775 (2007-05-01), None
patent: WO-2007/067616 (2007-06-01), None
patent: WO 2008/076437 (2008-06-01), None
patent: WO-2008/076437 (2008-06-01), None
patent: WO-2008/097541 (2008-08-01), None
patent: WO-2008/100384 (2008-08-01), None
patent: WO-2008/109167 (2008-09-01), None
patent: WO-2009019504 (2009-02-01), None
patent: WO-2009019505 (2009-02-01), None
patent: WO-2009137613 (2009-11-01), None
Acceleron Pharma Presents Positive Phase 1 Results Demonstrating ACE-011 Increases Markers of Bone Formation, Acceleron Pharma, pp. 1-2, retrieved from the Internet, www.acceleronpharma.com/contents
ews/press-releases/detail.jsp/q
ews-id/47> (2007).
Akel, S., et al, “Neutralization of Autocrine Transforming Growth Factor -β,” Stem Cells, 21:557-567 (2003).
Broxmeyer, H.E., et al, “Selective and indirect modulation of human multipotential and erythroid hematopoietic progenitor cell proliferation by recombinant human activin and inhibin,” Proc. Natl. Acad. Sci. USA, 85:9052-9056 (1988).
Burdette et al., “Activin A mediates growth inhibition and cell cycle arest through Smads in human breast cancer cells.” Cancer Research, 65(17):7968-7975; Abstract (2005).
Centrella et al., “Activin-A Binding and Biochemical Effects in Osteoblast-Enriched Cultures from Fetal-Rat Parietal Bone,” Molecular and Cellular Biology, 11(1):250-58 (1991).
Coerver, K.A., et al., “Activin Signaling through Activin Receptor Type II Causes the Cachexia-Like Symptoms in Inhibin-Deficient Mice,” Molecular Endocrinology, 10(5):534-543 (1996).
Daluiski et al., “Bone Morphogenetic Protein-3 is a Negative Regulator of Bone Density,” Nature Genetics, 27:84-88 (2001).
del Re et al., “Reconstitution and Analysis of Soluble Inhibin and Activin Receptor Complexes in a Cell-free System,” The Journal of Biological Chemistry, 279(51):53126-53135 (2004).
Donaldson, et al., “Activin and inhibin binding to the soluble extracellular domain of activin receptor II”, Endocrinology 140(4):1760-1766(1999).
Donaldson, et al., Molecular Cloning and Binding Properties of the Human Type II Activin Receptor, Biochemical and Biophysical Research Communications, 184(1):310-316(1992).
Fafioffe, et al.,“Activin and inhibin receptor gene expression in the ewe pituitary throughout the oestrous cycle,” Journal of Endocrinology, vol. 182, pp. 55-68 (2004).
Frigon, N.L., et al, “Regulation of Globin Gene Expression in Human K562 Cells by Recombinant Activin A,” Blood, 79(3):765-772 (1992).
Fuller et al., “Activin A Is an Essential Cofactor for Osteoclast Induction,” Biochemical and Biophysical Research Communications, 268:2-7 (2000).
Funaba et al., “Expression and Localization of Activin Receptors During Endochondral Bone Development,” European Journal of Endocrinology, 144:63-71 (2001).
Gaddy-Kurten et al., “Inhibin Suppresses and Activin Stimulates Osteoblastogenesis and Osteoclastogenesis in Murine Bone Marrow Cultures,” Endocrinology, 143(1):74-83 (2002).
Gamer et al., “BMP-3 is a Novel Inhibitor of Both Activin and BMP-4 Signaling in Xenopus Embryos,” Developmental Biology, 285:156-168 (2005).
Ge, G., et al., “GDF11 Forms a Bone Morphogenetic Protein 1-Activated Latent Complex That Can Modulate Nerve Growth Factor-Induced Differentiation of PC12 Cells”, Molecular and Cellular Biology, 25(14):5846-5858 (2005).
GenBank NM—001106,Homo sapiensactivin A receptor, type IIB (ACVR2B), mRNA, http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucleotide&val=116734707 (Downloaded on Jan. 29, 2007).
Gonzalez-Cadavid, N.F., et al., “Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting,” PNAS, 95:14938-14943 (1998).
Gray, et al., “Identification of a binding site on the type II activin receptor for activin and inhibin”, Journal of Biological Chemistry, 275(5):3206-3212(2000).
Greenwald, et al., “The BMP7/ActRII Extracellular Domain Complex Provides New Insights into the Cooperative Nature of Receptor Assembly,” Molecular Cell, vol. 11, 605-617 (2003).
Hamrick et al., “Bone Mineral Content and Density in the Humerus of Adult Myostatin-Deficient Mice,” Calcified Tissue International, 71:63-68 (2002).
Hamrick, “Increased Bone Mineral Density in the Femora of GDF8 Knockout Mice,” The Anatomical Record, Part A 272A:388-391 (2003).
Hamrick, M.W., et al., “Femoral Morphology and Cross-sectional Geometry of Adult Myostatin-deficien
Kumar Ravindra
Pearsall Robert Scott
Seehra Jasbir
Acceleron Pharma Inc.
Chandra Gyan
Ropes & Gray LLP
LandOfFree
Method of increasing red blood cell levels or treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of increasing red blood cell levels or treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of increasing red blood cell levels or treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4284425